Juno Therapeutics, Inc. (JUNO) Downgraded by BidaskClub to “Buy”

BidaskClub downgraded shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a strong-buy rating to a buy rating in a research note issued to investors on Tuesday, July 11th.

JUNO has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Juno Therapeutics from a buy rating to a hold rating in a report on Tuesday, May 2nd. FBR & Co restated a hold rating on shares of Juno Therapeutics in a report on Thursday, May 18th. Vetr downgraded shares of Juno Therapeutics from a buy rating to a hold rating and set a $28.85 price objective on the stock. in a report on Monday, June 26th. Citigroup Inc. decreased their price objective on shares of Juno Therapeutics from $34.00 to $30.00 and set a buy rating on the stock in a report on Tuesday, April 4th. Finally, Wedbush reiterated a neutral rating and issued a $24.00 price objective on shares of Juno Therapeutics in a report on Friday, May 5th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $30.86.

Juno Therapeutics (NASDAQ JUNO) opened at 28.90 on Tuesday. The company has a 50-day moving average of $28.51 and a 200-day moving average of $24.26. The firm’s market capitalization is $3.01 billion. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $35.04.

Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.24. The firm had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. Juno Therapeutics’s quarterly revenue was down 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.64) earnings per share. On average, equities analysts predict that Juno Therapeutics will post ($3.05) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Juno Therapeutics, Inc. (JUNO) Downgraded by BidaskClub to “Buy”” was first posted by BBNS and is owned by of BBNS. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://baseballnewssource.com/markets/juno-therapeutics-inc-juno-downgraded-by-bidaskclub-updated-updated-updated/1198368.html.

In other news, Director Jay T. Flatley acquired 20,000 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The stock was acquired at an average price of $24.76 per share, with a total value of $495,200.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the company’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Insiders sold 8,041,500 shares of company stock worth $217,230,360 over the last 90 days. 15.26% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can boosted its stake in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 3,800 shares in the last quarter. Brighton Jones LLC purchased a new stake in Juno Therapeutics during the second quarter valued at $260,000. Nisa Investment Advisors LLC purchased a new stake in Juno Therapeutics during the first quarter valued at $200,000. CAPROCK Group Inc. purchased a new stake in Juno Therapeutics during the second quarter valued at $299,000. Finally, Russell Investments Group Ltd. purchased a new stake in Juno Therapeutics during the fourth quarter valued at $204,000. 64.60% of the stock is owned by institutional investors and hedge funds.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.